Skip to main content

Advertisement

SpringerLink
Log in

Subconjunctival bevacizumab in the impending recurrent pterygia

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The aim of this study is to evaluate the efficacy and safety of subconjunctival bevacizumab injection(s) in the treatment of impending recurrent pterygia. Twenty-three eyes of 23 patients who developed impending recurrence after pterygium surgery with conjunctival autografting and were treated with subconjunctival bevacizumab injection(s) (2.5 mg/0.1 mL) were included in the study. Anterior segment photographs were taken prior to and at 1 week, 1, 3 and 6 months after the injection, and at the end of the follow-up period. Image analysis was performed using an image processing and analysis software program. Recurrence rate and complications were recorded. The mean age and follow-up time of the patients were 51.2 ± 6.2 (31–60 years) and 16.8 ± 3.1 (12–22 months), respectively. The average number of injections was 2 ± 0.78 (1–3). Sixteen eyes required re-injection (two injections in nine eyes, three injections in seven eyes), due to progression of vascularization. There were significant differences between size percentage of lesions before injection and at 1 week, 1, 3 and 6 months after the injection (p < 0.05 for all). Corneal recurrence developed in only one patient and no ocular or systemic side-effects of bevacizumab were observed. Repeated injections of bevacizumab may help to prevent the high recurrence rate of residual impending pterygium, due to its adjuvant role in decreasing lesion size, especially in the first year after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33:23–28

    Article  CAS  PubMed  Google Scholar 

  2. Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69:925–927

    Article  CAS  PubMed  Google Scholar 

  3. Mansour AM (2009) Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol 93:864–865

    Article  CAS  PubMed  Google Scholar 

  4. Teng CC, Patel NN, Jacobson L (2009) Effect of subconjunctival bevacizumab on primary pterygium. Cornea 28:468–470

    Article  PubMed  Google Scholar 

  5. Kria L, Ohira A, Amemiya T (1996) Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 98:195–201

    Article  CAS  PubMed  Google Scholar 

  6. Lee DH, Cho HJ, Kim JT et al (2001) Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20:738–742

    Article  CAS  PubMed  Google Scholar 

  7. Jin J, Guan M, Sima J et al (2003) Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22:473–477

    Article  PubMed  Google Scholar 

  8. Gebhardt M, Mentlein R, Schaudig U et al (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112:1023–1030

    Article  PubMed  Google Scholar 

  9. Prabhasawat P, Tesavibul N, Leelapatranura K et al (2006) Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 113:1102–1109

    Article  PubMed  Google Scholar 

  10. Cardillo JA, Alves MR, Ambrosio LE et al (1995) Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Ophthalmology 102:1949–1952

    Article  CAS  PubMed  Google Scholar 

  11. Hosseini H, Nejabat M, Mehyar M et al (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 35:745–748

    Article  Google Scholar 

  12. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552

    Article  PubMed  Google Scholar 

  13. Manzano RP, Peyman GA, Khan P et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804–807

    Article  PubMed Central  PubMed  Google Scholar 

  14. Kim TI, Kim SW, Kim S et al (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27:349–352

    Article  PubMed  Google Scholar 

  15. Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579

    Article  CAS  PubMed  Google Scholar 

  16. FallahTafti MR, Khosravifard K, Mohammadpour M et al (2011) Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 30:127–129

    Article  Google Scholar 

  17. Wu PC, Kuo HK, Tai MH et al (2009) Topical bevacizumab eyedrops for limbal-conunctival neovascularization in impending recurrent pterygium. Cornea 28:103–104

    Article  PubMed  Google Scholar 

  18. Fallah MR, Khosravi K, Hashemian MN et al (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35:17–22

    Article  CAS  PubMed  Google Scholar 

  19. Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium. Cornea 31:155–161

    Article  PubMed  Google Scholar 

  20. Prabhasawat P, Barton K, Burkett G et al (1997) Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology 104:974–985

    Article  CAS  PubMed  Google Scholar 

  21. Shenasi A, Mousavi F, Shoa-Ahari S, Rahmi-Ardabili B, Fouladi RF (2011) Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea 30:1219–1222

    PubMed  Google Scholar 

  22. Bahar I, Kaiserman I, McAllum P et al (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142–147

    Article  PubMed  Google Scholar 

  23. Papathanassiou M, Theodossiadis PG, Liakaros VS et al (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145:424–431

    Article  CAS  PubMed  Google Scholar 

  24. You IC, Kang IS, Lee SH, Yoon KC (2009) Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 87:653–658

    Article  CAS  PubMed  Google Scholar 

  25. Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375–1382

    Article  CAS  PubMed  Google Scholar 

  26. Hurmeric V, Mumcuoglu T, Erduman C et al (2008) Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 27:357–362

    Article  PubMed  Google Scholar 

  27. Hirst LW, Sebban A, Chant D (1994) Pterygium recurrence time. Ophthalmology 101:755–758

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Faculty of Medicine, Baskent University, Fevzi Cakmak Cad. 10. Sokak, 06490, Bahcelievler, Ankara, Turkey

    Sezin Akca Bayar

  2. Department of Ophthalmology, Faculty of Medicine, Izmir University, Izmir, Turkey

    Cem Kucukerdonmez

  3. Department of Ophthalmology, Fehime Faik Kocagoz Hospital, Soke, Aydin, Turkey

    Ozlem Oner

  4. Department of Ophthalmology, Bayındır Hospital, Ankara, Turkey

    Yonca A. Akova

Authors
  1. Sezin Akca Bayar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cem Kucukerdonmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozlem Oner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonca A. Akova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sezin Akca Bayar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bayar, S.A., Kucukerdonmez, C., Oner, O. et al. Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol 34, 541–547 (2014). https://doi.org/10.1007/s10792-013-9852-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-013-9852-1

Keywords

Search

Navigation